Drug development and diabetes: can we ensure an open environment for their data?

The development of new drugs might contribute to the defeat of some diseases, including diabetes, for which no cure has yet been found. New drugs are necessary and very welcome, provided that they are launched on the market following thorough, reliable and independent clinical evaluation of their safety and effectiveness. This article digs into this issue, providing an example of the repercussions that market pressures and inadequate clinical reporting have had in the lives of people with diabetes.
drugs, thiazolidinedione, WHO, OGLD, FDA